Drugs

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis – Mount Sinai Department of Medicine

John Mascarenhas/primeinc.org

Mar 27, 2025, 07:24

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis – Mount Sinai Department of Medicine

Mount Sinai Department of Medicine shared a post on LinkedIn:

“John Mascarenhas, MD, discusses his research on myelofibrosis – the first study to evaluate a combination therapy approach instead of a single treatment.

“We are hopeful this study will mark the beginning of a new era in myelofibrosis treatment,” said Dr. Mascarenhas. “Our findings highlight the potential of combination therapies to achieve deeper and more durable responses.”

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Authors: Raajit K. Rampal, John Mascarenhas et al.

Pelabresib plus ruxolitinib

Aaron T. Gerds Alberto Álvarez-Larrán Alessandro Lucchesi Alessandro M. Vannucchi Andrea Patriarca Andrew T. Kuykendall Anna-Maria Jegg Barbara Brown cancer Claire N. Harrison David Lavie Dominik Chraniuk Elisabetta Abruzzese Francesca Palandri Jean-Jacques Kiladjian John Mascarenhas Joseph M. Scandura Morgan Harris Moshe Talpaz OncoDaily Oncology Prithviraj Bose Qing Li Raajit K. Rampal Rainer Boxhammer Ruben Mesa Sarah-Katharina Kays Sebastian Grosicki Stephen T. Oh Sung-Eun Lee Vikas Gupta

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts